Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

SLU-PP-332: what the published research shows

A review of the published literature on SLU-PP-332, a pan-ERR agonist investigated as an exercise mimetic, covering in vitro metabolism, structure-activity relationships, and pilot studies in human myoblasts.

peptides-pro Editorial

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), a class of orphan nuclear receptors that regulate mitochondrial metabolism and exercise-responsive transcription [2]. It is also known as SLU-PP-332 and has been described as a pan-ERR agonist and exercise mimetic in the scientific literature [1][4]. The compound is widely used as a chemical probe for ERR activation, though its structural features governing potency, efficacy, selectivity, and drug-like properties have only recently been systematically elucidated [2].

The work on SLU-PP-332 centres on the estrogen-related receptor (ERR) family, a group of orphan nuclear receptors that act as master regulators of mitochondrial metabolism and exercise-responsive transcription [2].

Research Studies

SLU-PP-332 and in vitro metabolism in human liver fractions

An in vitro study characterised SLU-PP-332 and the related compound SLU-PP-915 using liquid chromatography-high resolution tandem mass spectrometry (LC-HRMS/MS) [1]. The researchers prepared in vitro metabolic transformation products of both compounds using human liver S9 fractions [1]. The study was conducted in the context of sports drug testing, as ERR agonists are considered potentially relevant for doping control programs [1]. The findings describe the analytical characterisation and metabolic pathways of SLU-PP-332 in a human liver fraction model, but do not report physiological effects in humans [1].

SLU-PP-332 and structure-activity relationships for ERR activation

A comprehensive structure-activity relationship (SAR) analysis of the SLU-PP-332 scaffold was reported, integrating chemical synthesis, cell-based functional assays, and downstream gene-expression profiling [2]. This work aimed to elucidate the structural features that govern potency, efficacy, selectivity, and drug-like properties of SLU-PP-332 and its analogues [2]. The study was conducted in cell-based systems and provides a framework for understanding how modifications to the SLU-PP-332 scaffold affect ERR signalling [2]. The findings are based on in vitro assays and do not constitute evidence of efficacy in whole organisms [2].

SLU-PP-332 and ERR activation in myoblasts from inactive women

A pilot study evaluated the targeting of ERRs in myoblasts isolated from the skeletal muscle of inactive women [3]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity [3]. The study assessed metabolic and expression changes associated with ERR activation in these cells [3]. This was an in vitro study using primary human myoblasts, and the results are specific to that cell model and population [3]. The study did not administer SLU-PP-332 to human participants; it investigated the effects of ERR activation in isolated cells [3].

SLU-PP-332 and exercise mimetic potential in preclinical models

SLU-PP-332 has been described as an exercise mimetic that triggers human physiological processes similar to those initiated by physical activity [1]. In the context of doping control, exercise mimetics are prohibited by the World Anti-Doping Agency (WADA) because they mimic physical activity and may prevent the development and progression of chronic metabolic diseases, including obesity and Type 2 diabetes [4]. The pharmacological activation of ERRα/β/γ has been proposed as a molecular strategy to mimic exercise-induced benefits, and SLU-PP-332 is a small, synthetic ERRα/β/γ agonist that has been studied for these purposes [4][5]. These reports are based on preclinical and in vitro evidence; no human clinical trials of SLU-PP-332 have been published in the evidence reviewed here.

SLU-PP-332 and metabolic syndrome in animal models

A synthetic ERR agonist, SLU-PP-332, has been reported to alleviate metabolic syndrome in preclinical models [7]. The study described the development of SLU-PP-332 as an agonist and its effects on metabolic parameters in animals [7]. This research is animal-only and does not provide data on human outcomes [7]. The findings support the investigation of ERR agonists as potential therapeutics for metabolic diseases, but they do not establish safety or efficacy in humans [7].

SLU-PP-332 and aerobic exercise capacity in animal models

An orally active ERR agonist, SLU-PP-915, has been shown to enhance aerobic exercise capacity in animal models [6]. SLU-PP-915 is a related compound, and the study reported that ERRs regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle, and are essential for skeletal muscle adaptation to aerobic exercise [6]. While this study focused on SLU-PP-915, it provides context for the ERR agonist class to which SLU-PP-332 belongs [6]. The findings are from animal models and have not been confirmed in humans [6].

SLU-PP-332 and doping control analysis

Analytical methods have been developed for the identification of in vitro metabolites of SLU-PP-332 for doping-control purposes [4]. The World Anti-Doping Agency prohibits the use of exercise mimetics and metabolic modulators in sports, and SLU-PP-332 is a small, synthetic ERRα/β/γ agonist that has been considered in this context [4]. These studies are focused on detection and do not address therapeutic potential or safety [4].

SLU-PP-332 and pharmacological activation of ERRs: a systematic review

A systematic review examined the current evidence on the physiological, molecular, and clinical effects of pharmacological activation of ERRα/β/γ as an exercise mimetic [5]. The review aimed to summarise the potential therapeutic applications of ERR activation in the context of physical inactivity and chronic diseases [5]. The evidence reviewed is largely preclinical, and the review highlights the need for further research to establish clinical utility [5].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp